MRK Stock Recent News

Beyond analysts' top -and-bottom-line estimates for Merck (MRK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.

Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have massive total return potential.

NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Merck & Co., Inc. (NYSE: MRK) on behalf of long-term stockholders following a class action complaint that was filed against Merck on February 12, 2025 with a Class Period from February 3, 2022, to February 3, 2025. Our investigation concerns whether the board of directors of Merck have breached their fiduciary duties to the company.

Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Growth is driven by heightened demand for water and wastewater treatment due to water scarcity and stringent environmental regulations. Key industries like pharmaceuticals, food and beverages, and water treatment are increasingly adopting microfiltration technology for its efficiency and sustainability. However, high initial and operational costs present challenges, particularly for small-scale and developing regions. Advancements in hollow fiber and polymeric membrane designs offer significant growth opportunities, despite ongoing challenges with membrane fouling. Currently, the Asia Pacific region leads the market, with major growth in China, India, and Japan. Principal market players include Merck KGaA, Sartorius AG, and Hydranautics. Growth is driven by heightened demand for water and wastewater treatment due to water scarcity and stringent environmental regulations. Key industries like pharmaceuticals, food and beverages, and water treatment are increasingly adopting microfiltrati

Dr. Scott Gottlieb, former FDA Commissioner, joins 'Squawk Box' to discuss current pharmaceutical imports under investigation, moving production for branded and generic drugs elsewhere, and much more.

Unprecedented Opportunities: Recent market panic has created deep discounts among world-class blue-chip companies trading at 52-week lows, offering up to 100% potential returns and secure yields approaching 8%. Trade War Realities: Despite severe pessimism driven by historic tariff increases (highest since 1909), the actual economic impact might be significantly less dire, potentially avoiding recession altogether. Institutional strategies, such as pensions and risk parity funds, may soon trigger substantial stock-buying due to automatic rebalancing. This would provide strong support and fuel market rallies from oversold conditions.

Merck and AbbVie are included in this Analyst Blog.

The latest trading day saw Merck (MRK) settling at $79.17, representing a -0.01% change from its previous close.